BROWN RUDNICK LLP for APOTEX CORPORATION
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
S. 1315 & H.R. 3777 - The Drug Price Competition Act of 2009; H.R. 1706 Protecting Consumer Access to Generic Drugs Act; S. 369 - Preserve Access to Affordable Generics Act; House Energy and Commerce Committee Drug Import Safety Discussion Draft Amend FDCA concerning correction of Orange Book listings
Foreign entity interest: ApoSherm Inc., the parent company of Apotex Corp., has direct and/or indirect ownership interest in companies that develop, manufacture, and/or sell generic drugs, and therefore has an interest in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA LAYMAN | SPA, Sen Stabenow(05-07) |
| HENRY W MENN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.